These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38496821)

  • 21. The Landscape of Somatic Genetic Alterations in Breast Cancers from
    Mandelker D; Kumar R; Pei X; Selenica P; Setton J; Arunachalam S; Ceyhan-Birsoy O; Brown DN; Norton L; Robson ME; Wen HY; Powell S; Riaz N; Weigelt B; Reis-Filho JS
    JNCI Cancer Spectr; 2019 Jun; 3(2):pkz027. PubMed ID: 31360903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.
    Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T
    Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: Evidence for further locus heterogeneity.
    Smith PS; West H; Whitworth J; Castle B; Sansbury FH; Warren AY; Woodward ER; Tischkowitz M; Maher ER
    Genes Chromosomes Cancer; 2021 Jan; 60(1):5-16. PubMed ID: 32830346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of Germline Pathogenic Variants in Renal Cancer Predisposition Genes in a Population-Based Study of Renal Cell Carcinoma.
    Bruinsma F; Harraka P; Jordan S; Park DJ; Pope B; Steen J; Milne RL; Giles GG; Winship I; Tucker KM; Southey MC; Nguyen-Dumont T
    Cancers (Basel); 2024 Aug; 16(17):. PubMed ID: 39272843
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Brock P; Liynarachchi S; Nieminen TT; Chan C; Kohlmann W; Stout LA; Yao S; La Greca A; Jensen KE; Kolesar JM; Salhia B; Gulhati P; Hicks JK; Ringel MD
    Thyroid; 2024 Apr; 34(4):477-483. PubMed ID: 38279823
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetic and epigenetic alterations during renal carcinogenesis.
    Arai E; Kanai Y
    Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel.
    Coffee B; Cox HC; Kidd J; Sizemore S; Brown K; Manley S; Mancini-DiNardo D
    Cancer Genet; 2017 Feb; 211():5-8. PubMed ID: 28279308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
    Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
    BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different risk genes contribute to clear cell and non-clear cell renal cell carcinoma in 1532 Japanese patients and 5996 controls.
    Sekine Y; Iwasaki Y; Aoi T; Endo M; Hirata M; Kamatani Y; Matsuda K; Sugano K; Yoshida T; Murakami Y; Fukui T; Akamatsu S; Ogawa O; Nakagawa H; Numakura K; Narita S; Habuchi T; Momozawa Y
    Hum Mol Genet; 2022 Jun; 31(12):1962-1969. PubMed ID: 35764097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
    Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
    Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline pathogenic variants in 786 neuroblastoma patients.
    Kim J; Vaksman Z; Egolf LE; Kaufman R; Evans JP; Conkrite KL; Danesh A; Lopez G; Randall MP; Dent MH; Farra LM; Menghani N; Dymek M; Desai H; Hausler R; ; ; ; Auvil JG; Gerhard DS; Hakonarson H; Maxwell KN; Cole KA; Pugh TJ; Bosse KR; Khan J; Wei JS; Maris JM; Stewart DR; Diskin SJ
    medRxiv; 2023 Jan; ():. PubMed ID: 36747619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
    Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.
    Pavlovica K; Irmejs A; Noukas M; Palover M; Kals M; Tonisson N; Metspalu A; Gronwald J; Lubinski J; Murmane D; Kalnina A; Loza P; Maksimenko J; Trofimovics G; Subatniece S; Daneberga Z; Miklasevics E; Gardovskis J
    Eur J Med Genet; 2022 May; 65(5):104477. PubMed ID: 35314380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.
    Domchek SM; Yao S; Chen F; Hu C; Hart SN; Goldgar DE; Nathanson KL; Ambrosone CB; Haiman CA; Couch FJ; Polley EC; Palmer JR;
    JAMA Oncol; 2021 Jul; 7(7):1045-1050. PubMed ID: 34042955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
    Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma.
    Ricketts C; Zeegers MP; Lubinski J; Maher ER
    PLoS One; 2009 Jun; 4(6):e6037. PubMed ID: 19551141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
    Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
    Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.